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Abstract
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade.
Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within
the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on
infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For
brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC
inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been
conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for
clinical management have been developed.
Introduction
Immunotherapeutic agents and small molecules for mole-
cular targeted treatment have profoundly changed the
landscape of antineoplastic therapy in hematology and
oncology. Their impact on innate and adaptive immunity is
not yet completely understood. Given to heavily pretreated
patients and combined with other anticancer treatment
modalities, they may be associated with unexpected,
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potentially serious infections. However, in heavily pre-
treated patients, particularly those with chronic lymphocytic
leukemia and other indolent B-cell lymphomas, it may be
difficult to identify a causal relationship between those
infections and drugs administered for lymphoma treatment.
As immune-related autoinflammatory reactions are typical
adverse events (irAE) occurring in many of these patients,
differential diagnostic efforts to distinguish those reactions
from infections are crucial. In patients affected by irAE,
immunosuppressive treatment will often be required,
resulting in secondary infections. This complex scenario
calls for a high alertness to formerly unexpected clinical
complications among hematologists and oncologists using
these newer antineoplastic agents. At the same time,
unjustified attribution of infections to these agents and
recommendations for routine antimicrobial prophylaxis
should be avoided. This position paper updates our current
knowledge of infections associated with these agents and
provides recommendations for a rational clinical manage-
ment of prevention and treatment of infections in patients
treated with immunotherapeutic and molecular targeted
antineoplastic agents.
Immunotherapeutic and molecular targeted anti-
neoplastic agents including checkpoint inhibitors, idelalisib,
mTOR inhibitors, and, to a lesser extent, ibrutinib have
been associated with drug-related pneumonitis. This pneu-
monitis is clinically indistinguishable from infectious
pneumonias, and the diagnosis relies on the exclusion of
differential diagnoses. The specific management of drug-
related pneumonitis includes drug withdrawal and con-
sideration for corticosteroids according to the severity.
Methods
A group of experts in hematology and oncology, infectious
diseases (including virology), pulmonology, diagnostic
radiology and hematopoietic stem cell transplantation from
six European countries was nominated by the ECIL
organization committee in 2016. Immunotherapeutic and
molecular targeted agents, which have become available
for clinical use within the past decade, including bren-
tuximab vedotin, blinatumomab and immune checkpoint
inhibitors as well as HDAC inhibitors, ibrutinib, idelalisib,
mTOR inhibitors, ruxolitinib and venetoclax, were
addressed. Other agents approved during the last 10 years
(such as obinutuzumab, newer proteasome inhibitors,
pomalidomide, daratumumab, elotuzumab or inotuzumab
ozogamicin) were excluded, because thorough literature
searches did not identify relevant infection risks attribu-
table to these agents, or no new signals as compared to
older drugs from the same class of agents were found, or
because their approval was extremely limited (such as
mogamulizumab). A systematic literature review including
research papers, case reports, published study results and
meta-analyses or review articles was conducted using
drug- and class-based search strings: “(agent)” OR
“(class)” AND “mode of action” OR “approval” OR
“study” OR “infection” OR “infectious” OR “toxicity”
OR “adverse events” OR “viral” OR “bacterial” OR
“Pneumocystis” OR “fungal” OR “pneumonia” OR
“pneumonitis” OR “CNS” OR “hepatitis” OR “cytome-
galovirus” OR “immune-related” OR “prophylaxis”. The
group compiled an extensive slide set including mode of
action, state of approval, impact on innate and adaptive
immunity, reported infectious complications and recom-
mendations for clinical practice. After mail-based and
face-to-face group discussions, the revised and consented
slides were presented to the plenary of the seventh ECIL
conference in Sophia Antipolis, France, on 22 and 23
September 2017. The plenary decided to abandon grading
and strength of recommendations, because the data com-
prised represent a “moving target” with a rapidly growing
body of reports. In order to provide a critical and detailed
summary of the current knowledge in the field, the result
should be published as an ECIL position paper.
All co-authors have been actively involved in the pre-
paration and discussion of this manuscript.
The agents included are addressed in the following
sequence: (1) immunotherapeutic drugs and (2) molecular
targeted drugs/drug classes, both in alphabetical order.
A summary of available data as well as ECIL recom-
mendations is listed in Table 1.
Immunotherapeutic agents (blinatumomab,
brentuximab vedotin, immune checkpoint
inhibitors): characterization, impact on
immunity, reported infectious complications
and recommendations for clinical practice
Blinatumomab
Blinatumomab is a bispecific T-cell engaging (BiTE) anti-
body, approved for the treatment of Philadelphia-
chromosome negative relapsed or refractory B-precursor
acute lymphoblastic leukemia (R/R ALL) [1]. It is made of
a single-chain anti-CD19 antibody attached by a flexible
linker peptide to a single-chain anti-CD3 antibody. It
induces a close contact between effector T-cells and CD19-
positive cells, with subsequent T-cell activation and targeted
lysis of CD19-positive cells [2]. CD19 is expressed in all
B-cell lineage leukemia, and a majority of B-cell lineage
lymphomas. In normal cells, it is expressed all along B-cell
differentiation, with the exception of pluripotent stem cells
and plasma cells [3].
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology.. . . 845
Ta
bl
e
1
S
um
m
ar
y
of
dr
ug
ch
ar
ac
te
ri
st
ic
s,
re
po
rt
ed
in
fe
ct
io
us
co
m
pl
ic
at
io
ns
an
d
E
C
IL
re
co
m
m
en
da
tio
ns
fo
r
cl
in
ic
al
pr
ac
tic
e
C
la
ss
of
ag
en
ts
A
ge
nt
Im
pa
ct
on
im
m
un
e
sy
st
em
In
fe
ct
io
us
ev
en
ts
E
C
IL
re
co
m
m
en
da
tio
ns
C
D
19
-d
ir
ec
te
d
C
D
3
bi
sp
ec
ifi
c
T
-c
el
l
en
ga
ge
r
B
lin
at
um
om
ab
B
-c
el
l
ap
la
si
a;
hy
po
ga
m
m
ag
lo
bu
lin
em
ia
;
ne
ut
ro
pe
ni
a
N
o
cl
ea
r
ev
id
en
ce
of
in
cr
ea
se
d
in
fe
ct
io
n
ra
te
•C
on
si
de
ra
tio
n
of
Ig
G
su
bs
tit
ut
io
n
in
ca
se
of
se
ri
ou
s
in
fe
ct
io
n
A
nt
i-
C
D
30
an
tib
od
y
B
re
nt
ux
im
ab
ve
do
tin
P
oo
rl
y
de
fi
ne
d;
im
pa
ir
m
en
t
of
m
em
or
y
ce
ll
ge
ne
ra
tio
n
an
d
su
rv
iv
al
;
tr
an
si
en
t
ne
ut
ro
pe
ni
a
P
ne
um
oc
ys
tis
pn
eu
m
on
ia
;
C
M
V
an
d
H
B
V
re
ac
tiv
at
io
n;
JC
vi
ru
s-
as
so
ci
at
ed
P
M
L
•C
M
V
m
on
ito
ri
ng
;
•N
o
ro
ut
in
e
sy
st
em
ic
an
tim
ic
ro
bi
al
pr
op
hy
la
xi
s;
•H
ig
h
al
er
tn
es
s
to
P
M
L
Im
m
un
e
ch
ec
kp
oi
nt
in
hi
bi
to
rs
Ip
ili
m
um
ab
(a
nt
i-
C
T
L
A
4)
;
N
iv
ol
um
ab
,
pe
m
br
ol
iz
um
ab
,
at
ez
ol
iz
um
ab
an
d
ot
he
rs
(a
nt
i-
P
D
-1
/a
nt
i-
P
D
-L
1)
N
o
di
re
ct
im
m
un
os
up
pr
es
si
on
F
re
qu
en
t
im
m
un
e-
re
la
te
d
au
to
-
in
fl
am
m
at
or
y
co
m
pl
ic
at
io
ns
;
in
fe
ct
io
ns
du
e
to
an
ti-
in
fl
am
m
at
or
y/
im
m
un
os
up
pr
es
si
ve
ag
en
ts
•H
ig
h
al
er
tn
es
s
to
in
fe
ct
io
ns
if
an
ti-
in
fl
am
m
at
or
y/
im
m
un
os
up
pr
es
si
ve
ag
en
ts
ar
e
re
qu
ir
ed
;
•P
ne
um
oc
ys
tis
pr
op
hy
la
xi
s
if
gl
uc
oc
or
tic
os
te
ro
id
m
ed
ic
at
io
n
ex
ce
ed
s
3−
4
w
ee
ks
B
ru
to
n
T
yr
os
in
e
K
in
as
e
In
hi
bi
to
r
Ib
ru
tin
ib
T
ol
l-
lik
e
re
ce
pt
or
-m
ed
ia
te
d
re
co
gn
iti
on
of
in
fe
ct
io
us
ag
en
ts
;
M
at
ur
at
io
n,
re
cr
ui
tm
en
t
an
d
fu
nc
tio
n
of
in
na
te
im
m
un
e
ce
lls
,
in
cl
ud
in
g
ne
ut
ro
ph
ils
,
m
on
oc
yt
es
an
d
m
ac
ro
ph
ag
es
;
R
eg
ul
at
io
n
of
N
L
R
P
3
in
fl
am
m
as
om
e
ac
tiv
at
io
n
S
lig
ht
in
cr
ea
se
in
ba
ct
er
ia
l,
fu
ng
al
an
d
vi
ra
l
in
fe
ct
io
ns
,
pa
rt
ic
ul
ar
ly
in
he
av
ily
pr
et
re
at
ed
pa
tie
nt
s;
C
er
eb
ra
l
as
pe
rg
ill
os
is
in
pa
tie
nt
s
tr
ea
te
d
fo
r
ly
m
ph
om
a
w
ith
br
ai
n
in
vo
lv
em
en
t
•U
pd
at
e
pr
ot
ec
tiv
e
va
cc
in
at
io
ns
be
fo
re
ib
ru
tin
ib
tr
ea
tm
en
t;
•I
nc
re
as
ed
al
er
tn
es
s
to
in
fe
ct
io
ns
;
•A
t
si
gn
s
of
in
fe
ct
io
n,
di
ag
no
st
ic
s
in
cl
ud
in
g
ba
ct
er
ia
l,
vi
ra
l
an
d
fu
ng
al
pa
th
og
en
s;
•N
o
ro
ut
in
e
sy
st
em
ic
an
tim
ic
ro
bi
al
pr
op
hy
la
xi
s
P
ho
sp
ha
tid
yl
in
os
ito
l-
3-
ki
na
se
in
hi
bi
to
r
Id
el
al
is
ib
D
ec
re
as
e
in
nu
m
be
r
an
d
fu
nc
tio
n
of
re
gu
la
to
ry
T
ce
lls
;
In
hi
bi
tio
n
of
N
K
ce
ll
an
d
ne
ut
ro
ph
il
in
fl
am
m
at
or
y
re
sp
on
se
;
N
eu
tr
op
en
ia
S
lig
ht
in
cr
ea
se
in
P
ne
um
oc
ys
tis
pn
eu
m
on
ia
•A
nt
i-
P
ne
um
oc
ys
tis
pr
op
hy
la
xi
s
(s
ee
la
be
l)
;
•C
he
ck
C
M
V
se
ro
st
at
us
an
d
co
ns
id
er
C
M
V
m
on
ito
ri
ng
;
•A
t
si
gn
s
of
in
fe
ct
io
n,
co
ns
id
er
im
m
un
e-
re
la
te
d
ad
ve
rs
e
re
ac
tio
n
H
is
to
ne
de
ac
et
yl
as
e
in
hi
bi
to
rs
V
or
in
os
ta
t,
pa
no
bi
no
st
at
,
ro
m
id
ep
si
n
In
hi
bi
tio
n
of
to
ll-
lik
e
re
ce
pt
or
-m
ed
ia
te
d
de
nd
ri
tic
ce
ll
an
d
m
ac
ro
ph
ag
e
fu
nc
tio
n
(s
en
si
ng
,
ph
ag
oc
yt
os
is
,
cy
to
ki
ne
pr
od
uc
tio
n,
ad
he
si
on
)
N
o
cl
ea
r
ev
id
en
ce
of
in
cr
ea
se
d
in
fe
ct
io
n
ra
te
•H
B
V
sc
re
en
in
g,
co
ns
id
er
at
io
n
of
an
tiv
ir
al
pr
op
hy
la
xi
s
in
H
B
sA
g-
or
an
ti-
H
B
c-
po
si
tiv
e
pa
tie
nt
s
m
T
O
R
in
hi
bi
to
rs
S
ir
ol
im
us
,
te
m
si
ro
lim
us
,
ev
er
ol
im
us
In
hi
bi
tio
n
of
T
-c
el
l
pr
ol
if
er
at
io
n,
an
tig
en
-
pr
es
en
tin
g
ce
lls
,
B
ce
lls
,
ne
ut
ro
ph
il
gr
an
ul
oc
yt
es
N
o
cl
ea
r
ev
id
en
ce
of
in
cr
ea
se
d
in
fe
ct
io
n
ra
te
•H
ig
h
al
er
tn
es
s
of
in
fe
ct
io
ns
;
•N
o
ro
ut
in
e
an
tim
ic
ro
bi
al
pr
op
hy
la
xi
s;
•A
t
si
gn
s
of
pu
lm
on
ar
y
in
fe
ct
io
n,
co
ns
id
er
im
m
un
e-
re
la
te
d
ad
ve
rs
e
re
ac
tio
n
Ja
nu
s
ki
na
se
in
hi
bi
to
r
R
ux
ol
iti
ni
b
In
hi
bi
tio
n
of
de
nd
ri
tic
ce
ll
an
d
C
D
4+
T
-c
el
l
fu
nc
tio
n;
R
ed
uc
tio
n
of
re
gu
la
to
ry
T
ce
lls
;
N
K
ce
ll
in
hi
bi
tio
n
M
ar
gi
na
lly
in
cr
ea
se
d
ri
sk
of
op
po
rt
un
is
tic
in
fe
ct
io
ns
;
O
cc
as
io
na
l
H
B
V
re
ac
tiv
at
io
n
•C
ar
ef
ul
m
on
ito
ri
ng
fo
r
in
fe
ct
io
ns
;
•H
B
V
sc
re
en
in
g,
pr
op
hy
la
ct
ic
en
te
ca
vi
r
in
H
B
sA
g-
or
an
ti-
H
B
c-
po
si
tiv
e
pa
tie
nt
s;
•M
T
B
sc
re
en
in
g
in
pa
tie
nt
s-
at
-r
is
k
846 G. Maschmeyer et al.
Even at very low doses, blinatumomab has been shown
to induce a rapid and sustained decrease of measurable
peripheral B cells [4, 5]. All B cells are depleted,
including CD19-negative plasma cells as a consequence
of precursors and CD19-positive plasmablast clearance.
A decrease of immunoglobulin (IgG, IgA, IgM) levels
has been reported with slow recovery at long-term follow-
up [6]. The exact impact on preexisting immunity is
unknown, and, although anticipated, a correlation with
increased risk of infection has not been proven. Interest-
ingly, CTL019, another anti-CD19 antibody-based
immunotherapy, also induces B-cell aplasia and hypo-
gammaglobulinemia, but stable titers of several vaccine-
and pathogen-specific serum immunoglobulin G and A
were noted [7].
The second known immunosuppressive effect of blina-
tumomab is neutropenia, with grade 3 neutropenia reported
in 18−32% of patients [1]. This rate is variable according to
the context, and in advanced ALL, grade 3 or higher neu-
tropenia has been shown to be 20% less frequent with bli-
natumomab than with chemotherapy (37.8% vs. 57.8%) [8].
In a follow-up of blood counts in patients treated with bli-
natumomab for R/R ALL, median neutrophil count
decreased in responders from 1.8 × 103/μL to 0.6 × 103/μL
on day 7, but did not decrease anymore during subsequent
cycles. Febrile neutropenia was not reported in clinical
studies in the context of MRD-positive ALL or NHL, but
grade 3 events occurred in up to 24% of patients in R/R
ALL [5, 9].
Overall, infections of all grades were reported in
45% of treated patients, with grade 3 or higher in 27% [1].
This infection rate must be interpreted cautiously in
the context of advanced hematologic malignancies and
heavily pretreated patients. Results of the phase-3
TOWER trial were confirmatory, showing lower grade 3
or higher infection rates in the blinatumomab group
compared to chemotherapy (34.1% vs. 52.3%) [8]. Inva-
sive fungal infections have been reported rarely,
and a recent review has identified ten reported cases
associated with blinatumomab use in ALL, again probably
linked to the context [10]. Venous catheter-related
infections constitute an important concern, blinatumo-
mab being administered by continuous infusion for 2
−4 weeks [11].
In conclusion, blinatumomab has not been associated
with a high infectious risk, but some practical recom-
mendations can be made. A particular attention should
be put on central venous lines management, and
clinicians should be alert for the risk of catheter-related
infections. Immunoglobulin level monitoring and sup-
plementation in case of low IgG concentration is recom-
mended, particularly in patients with a history of serious
infections [12].Ta
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Brentuximab vedotin
Brentuximab vedotin (BV) is an antibody-drug conjugate
(ADC) of a chimeric anti-CD30 antibody and the synthetic
anti-tubulin monomethyl auristatin E (MMAE). The ADC
binds to the membrane glycoprotein CD30, inducing sub-
sequent intracytosolic release of MMAE after internaliza-
tion and proteolytic cleavage of the dipeptidic ADC linker
[13]. The drug is approved for the treatment of relapsed or
refractory CD30-positive classical Hodgkin’s lymphoma
(HL), as consolidation therapy after autologous hemato-
poietic stem cell transplantation in HL, and for relapsed or
refractory anaplastic large T-cell lymphoma (ALCL) [14].
CD30 is a member of the Tumor Necrosis Factor
receptor superfamily, which is highly expressed by Reed-
Sternberg cells in HL and by malignant cells in ALCL. It
shows a variable level of expression on the surface of
malignant cells in other NHL. CD30 has a low level of
expression in normal cells, mainly restricted to a small
subset of activated B-, T- (CD4- and CD8-positive) and
natural killer (NK) cells [15]. CD30 has been shown to play
a complex role in immune response, which has not been
fully elucidated yet. Among other, it is thought to help to
maintain CD8-positive effector cell activity during antigenic
challenge [16]. It is involved in the transition from effector
cells to central memory cells and the survival of memory
cells. This role in the control of memory cells could help to
control pathogens such as listeria and mycobacteria [17].
Other mechanisms have also been suggested implying
CD30-positive cells in antimycobacterial immune response,
and those cells have been found in positive tuberculin skin
tests and TB-infected tissues [18]. By killing CD30-positive
cells, BV may induce an immune dysbalance facilitating
those infections, but it should be noted that no clinical
association has been demonstrated as yet.
Transient dose-dependent neutropenia is a commonly
observed side effect of BV. When given as a single agent in
relapsed or refractory HL or ALCL or for consolidation
therapy after autologous HSCT, BV was shown to induce
grade ≥3 neutropenia in 20−29% of patients. However,
febrile neutropenia was extremely rare [19–21]. In contrast,
myelosuppression appears to be an important concern when
BV is used in combination with chemotherapy. In a phase
3 study evaluating BV+AVD vs. ABVD in stage III or IV
HL, the use of BV was associated with a higher risk of
grade ≥3 neutropenia (58% vs. 45% respectively) and with
higher rates of febrile neutropenia, mainly during the first
cycle (9% vs. 4% respectively). The risk was reduced by
primary G-CSF prophylaxis [22].
Overall, BV does not appear to be associated with a high
risk of infectious complications. Phase 3 studies did not
show a higher infection rate in the BV group compared to
controls [21, 23]. A slightly higher overall infectious risk
was described in the BV+AVD group than in the ABVD
group, but was mitigated by G-CSF administration [22].
However, some specific concerns have been raised about
particular pathogens or situations.
Pneumonia has been reported in up to 10% of BV-treated
patients [14], with even higher rates when combined with
chemotherapy [24]. Pneumocystis pneumonia (PcP) was
rare (0.1−1%) [14]. Noninfectious pulmonary toxicity has
been reported [25], but is more likely to be attributable to
the coadministration of bleomycin, so that this combination
has become contra-indicated [9]. Large phase 3 studies did
not show pulmonary toxicity when BV was not combined
with bleomycin [21, 23].
Varicella Zoster Virus (VZV) and Herpes Simplex Virus
(HSV) infections are described as common side effect of
BV, with an incidence of 1−10% [149]. Extensive or dis-
seminated diseases have been reported [26, 27]; however, a
clear causal relationship is doubtful because of the impact of
many other risk factors in affected patients.
Although not described in pivotal studies, two case series
of cytomegalovirus (CMV) reactivation under BV have
been published, questioning the true incidence of this event
and a possible causal relationship. In allogeneic stem cell
recipients, 5 CMV viremias among 25 patients treated with
BV for HL recurring after allogeneic HSCT were reported.
Three patients required treatment and one died in the
setting of CMV reactivation [28]. Another report described
three cases of CMV reactivation with retinitis among
32 lymphoma patients treated with BV. Patients responded
to therapy, but two out of three relapsed after BV rechal-
lenge [29].
Concerns about a risk of JC virus (John Cunningham
polyoma virus) infection in patients treated with BV have
been raised early after the approval of BV. A boxed
warning was inserted in the drug label in 2012. At that time,
two proven and one probable case of progressive multifocal
leukoencephalopathy (PML) had been reported among 2000
patients treated worldwide [30]. Additional cases have been
described since then [31], with a total of 15 cases reported
until July 2015 to the FDA’s Adverse Event Reporting
System. The case fatality rate was 33.3% [32]. It must be
kept in mind that those reported cases do not prove a causal
relationship, as lymphoid malignancy, multiagent che-
motherapy or hematopoietic cell transplantation are PML
risk factors [33]. While there is no estimated PML incidence
known for patients with HL, the rate for those with NHL is
estimated to be 8.3 (95% CI 1.71–24.24) per 100,000
person-years [34].
For clinical practice, no specific recommendation can be
made with regards to antimicrobial prophylaxis. G-CSF
prophylaxis should be considered when BV is used in
combination with chemotherapeutic agents. PcP prophy-
laxis is not required, if BV is given without concomitant
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treatment [35]. The same rule applies to HSV and VZV
prophylaxis [36]. CMV should be taken into consideration
in case of symptoms compatible with infection, but no
prophylaxis, routine monitoring or preemptive therapy can
be recommended for patients undergoing treatment with
BV. For JC virus, no prophylaxis is available, but clinicians
should be alert and prompt a complete work-up in case of
new-onset neurological symptoms suggestive of PML. BV
should be withheld until PML has been excluded. In case of
confirmation, BV should be discontinued with the aim to
restore immunity against JC virus. In some cases this may
be complicated by an immune reconstitution inflammatory
syndrome [37]. However, in the case of BV-associated
PML, due to underlying disease and previous or concurrent
treatments, immune recovery is uncertain and the clinical
course is unpredictable. PML cases should be notified to
local competent authorities, in order to document this rare
possible association.
Immune checkpoint inhibitors
Immune checkpoint inhibition (ICI) has introduced a new
era of cancer therapy [38]. It represents a novel therapeutic
concept, as the primary target is the crosstalk between
immune cells and cancer cells in the tumor microenviron-
ment. Two immune checkpoints are currently targeted by
approved drugs: the programmed death 1 (PD-1)/PD-ligand
1 (PD-L1) axis as well as cytotoxic T-lymphocyte antigen-4
(CTLA-4). Blockade of the PD-1 or PD-L1 pathway has
been shown to exert therapeutic activity in patients with
Hodgkin lymphoma [39], head and neck squamous cell
carcinoma [40], advanced melanoma [41, 42], non-small
cell lung carcinoma [43, 44], and renal cell carcinoma
[45, 46]. Further indications may follow soon [47, 48]. The
anti-CTLA-4 antibody ipilimumab was the first immune-
checkpoint antibody approved for the treatment of patients
with advanced melanoma due to its survival benefit com-
pared to standard chemotherapy [41, 49, 50].
PD-1 is a cell surface coinhibitory receptor expressed
on T- and B-lymphocytes, monocytes and NK-cells after
activation [51]. To date, PD-L1 (B7-H1) and PD-L2 (B7-
DC) have been identified as ligands of PD-1. Both ligands
are expressed on antigen-presenting cells, and PD-L1 is
additionally detected on the surface of various non-
hematopoietic cells including tumor cells. The binding of
PD-1 to its ligands results in an inhibition of T-cell
receptor signaling on activated T-lymphocytes. In addi-
tion, the PD-1/PD-L1 pathway is a key component in the
development and maintenance of self-tolerance [52].
Furthermore, there is increasing evidence that the PD-1/
PD-L1 pathway is important in the pathogenesis of dif-
ferent tumors by inhibiting, and thus limiting antitumor
immune response [53–58].
CTLA-4 is a second immune-checkpoint expressed
during priming of T cells [41].
Inhibition of the PD-1/PD-L1 as well as the CTLA-4
pathway non-specifically activates the immune system
resulting in imbalance. A broad spectrum of immune-related
adverse events (irAE) may occur, involving the gut, skin,
endocrine glands, liver, lungs [59], and possibly other
organs [60, 61]. One rare irAE is neutropenia caused by
autoantibodies against neutrophils. Two cases have been
reported, one of them associated with a Staphylococcus
aureus infection [62, 63]. IrAE often require immunosup-
pressive medication, which in turn increases the suscept-
ibility to severe infections [47, 64, 65], resulting in up to
7.3% opportunistic infections in patients affected [66]. Few
data (mostly preclinical) report on higher risk for tubercu-
losis [67], histoplasmosis [68], and listeriosis [69, 70] due to
ICI. At present, the incidence of infection is undetermined
and the role of prophylactic antiviral and antifungal therapy
in this setting is undefined.
Prophylaxis of PcP should be considered if secondary
immunosuppression is given for at least 3 weeks [35, 71, 72]
As patients receiving ICI are at increased risk of infection due
to their underlying malignancy, it is recommended that they
receive all appropriate vaccines at the earliest possible
moment [73]. Future identification of biomarkers predicting
AE, e.g. microbiota in the gut, may help to facilitate pre-
emptive treatment [74, 75].
Molecular targeted agents (ibrutinib,
idelalisib, HDAC inhibitors, mTOR inhibitors,
ruxolitinib, venetoclax): characterization,
impact on immunity, reported infectious
complications and recommendations for
clinical practice
Ibrutinib
The inhibition of Bruton’s tyrosine kinase (BTK) is a cru-
cial strategy for treating B-cell malignancies. Ibrutinib, an
irreversible inhibitor of BTK, is now approved for the
treatment of chronic lymphocytic leukemia (B-CLL)
[76, 77], mantle cell lymphoma [78], marginal zone lym-
phoma [79], small lymphocytic lymphoma [80] and
Waldenström’s macroglobulinemia [81]. Ibrutinib is also
the first approved therapy for the treatment of chronic graft-
versus-host disease after failure of one or more lines of
systemic therapy [82]. BTK has been widely characterized
as a critical mediator of B-cell receptor signaling that reg-
ulates B-cell survival, activation, differentiation, and inter-
action with the environment [83]. Germline mutations in
the gene encoding for BTK result in an almost complete
absence of mature B cells and hypogammaglobulinemia, the
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hallmark of X-linked (Bruton’s) agammaglobulinemia [84].
Hence, BTK is essential in the development and functioning
of adaptive immunity. However, BTK also plays a major
role in innate immunity: (a) in Toll-like receptor-mediated
recognition of infectious agents, (b) in maturation, recruit-
ment and function of innate immune cells, including neu-
trophils, monocytes and macrophages, and (c) in regulating
NLRP3 inflammasome activation [85]. Thus, targeting BTK
with ibrutinib in a population already characterized by an
immune dysregulation (e.g. CLL) will most likely result in
an increased risk of infection.
Collectively, the randomized pivotal trials demonstrate
that upper respiratory tract infections are the most common
infectious complications in ibrutinib-treated patients, albeit
mostly self-resolving [76–81]. Pneumonia is the most
common serious infectious event. The frequency and pat-
tern of infections appears to reflect what is typically seen in
this B-cell malignancy population, rather than a drug-
specific adverse event profile. Infectious complications are
considerably fewer and less severe in treatment-naïve (TN)
compared with relapsed/refractory (R/R) patients, i.e., 13%
vs. 51% ≥ grade 3 infections: pneumonia (6% vs. 25%),
sepsis (0% vs. 7%), cellulitis (0% vs. 5%) sinusitis (0% vs.
5%) and bacteremia (0% vs. 4%) [86]. The infectious
morbidity appears to decrease over time; grade ≥ 3 infec-
tions are observed more frequently during the first 6 months
of therapy, often during the first 2−3 months. This trend is
related to the extended time from last chemotherapy in R/R
cases, early response and disease control, and the immu-
nomodulating potential of ibrutinib. In addition, prolonged
ibrutinib treatment results in a partial reconstitution of
the humoral immunity with stabilization or improvement
of immunoglobulin levels and of the normal B-cell popu-
lations [87].
Not unexpectedly in these often heavily pretreated
patients, opportunistic infections have been sporadically
reported, including cases of cryptococcal disease (menin-
goencephalitis/disseminated disease) [88–91], (miliary)
tuberculosis [92, 93], endemic mycosis, PML (in rituximab
pretreated patients) caused by JC virus [94–96], Epstein
−Barr Virus (EBV)-driven hemophagocytic syndrome [97],
and reactivations of Hepatitis B virus (HBV) [98, 99].
Following a report of five cases of PcP in a cohort of 96
patients [100], concern has risen that ibrutinib therapy could
increase the risk of PcP, although no other study has
reported a frequency above 1%. These PcP cases occurred
in previously untreated CLL patients receiving ibrutinib
monotherapy and presented in a “nontypical” way [100]: (a)
patients were asymptomatic or had only mild, often chronic
respiratory symptoms; (b) there was no long-term use of
steroids or other immunosuppressive drugs; (c) chest com-
puted tomography scan revealed nontypical multifocal
nodular infiltrates; (d) CD4+ T-cell counts were high (>500
per microliter), (e) and no patient required intravenous
therapy, adjunctive steroid treatment or mechanical venti-
lation. Of note, only one of these five cases was confirmed
by immunofluorescence, still considered the gold diagnostic
standard for PcP. The FDA Division of Pharmacovigilance
recently reviewed 13 additional cases of confirmed and
presumed PcP submitted to the FDA Adverse Event
Reporting System [101]. Contrary to the previous case
series, ten of these cases had refractory underlying disease
with prior exposure to other immunosuppressive agents
and six cases reported concomitant use of such agents.
Thus, although the inhibitory effect of ibrutinib on
interleukin-2-inducible kinase makes an increased risk for
PcP biologically plausible, PcP prophylaxis is not routinely
recommended; its risk-benefit should be outweighed in the
context of diminished T-cell immunity due to previous
(e.g. fludarabine-cyclophosphamide-rituximab therapy) or
concomitant therapy [35].
Among thousands of patients with a variety of B-cell
malignancies treated with ibrutinib, invasive mold infec-
tions have been reported only sporadically. The frequency
of invasive yeast and mold infections in the clinical studies
was low, ranging from 0 to 3.2% [1–6]. More recently, a
retrospective French survey reported 27 cases of invasive
aspergillosis from 16 centers [102]. Most cases occurred
early-on within a median of 3 months after starting ibrutinib
for relapsed/refractory disease. Cerebral involvement was
frequent (40%). Unfortunately, the survey did not report a
denominator, and the majority of patients had at least one
additional factor, aside from hypogammaglobulinemia, that
increased their risk for fungal infections [102]. During a
5-year period (2012−2016), invasive fungal infection
(including pulmonary and disseminated aspergillosis, pul-
monary cryptococcosis, and PcP) developed in 4.2% of
ibrutinib-treated patients at the Memorial Sloan Kettering
Cancer Center [103]. Experimental use of single-agent
ibrutinib in patients with primary central nervous system
lymphoma was associated with a 5−27% frequency of
invasive aspergillosis, including cerebral disease [104, 105].
Clearly BTK plays a role in innate fungal immune sur-
veillance (as demonstrated in Btk−/− mice studies [104]) via
a series of mechanisms mentioned before [85]. Obviously
ibrutinib impairs that fungal immune surveillance, thereby
contributing to the complex “net state of immunosuppres-
sion”, although the increased susceptibility to fungal disease
in ibrutinib-treated patients remains primarily dictated by
the status of the underlying lymphoid malignancy, the
combined action with other immunosuppressive therapies
and the environmental exposure to fungal pathogens
[103, 106]. However, these reports underscore the need for
heightened awareness and vigilance to identify any
change in fungal epidemiology in view of the rapidly
growing availability of novel therapeutic agents with
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immunosuppressive characteristics. Pending further epide-
miological data, routine mold-active prophylaxis is cur-
rently not recommended (outside the setting of severe
graft-versus-host disease post-allogeneic stem cell trans-
plantation, where ibrutinib may become a treatment option).
It must be kept in mind that mold-active azoles interfere
with ibrutinib elimination by inhibiting the CYP3A4
enzyme system, potentially increasing the risk of adverse
events [107]. However, as the indications for ibrutinib use
continue to expand, better identification of risk factors for
invasive fungal disease may define populations in which
monitoring and antifungal prophylaxis can be studied as
potential preventive strategies [103].
Guidelines recommend vaccination against influenza and
pneumococcal disease in patients with B-cell malignancies
[73, 108]. However, recent prospective data demonstrate
that ibrutinib may dramatically impair adequate serological
responses to vaccination [109, 110]; hence, clinicians may
consider vaccinating patients before the initiation of anti-
neoplastic therapy.
Finally, there have been sporadic reports of pneumonitis
in patients receiving ibrutinib [111]. These cases present
early (1−4 months) after initiation of therapy and are
clinically indistinguishable from infectious complications
(e.g. PcP or viral pneumonitis). Diagnosis is established by
ruling out other differential diagnoses; treatment includes
ibrutinib withdrawal and corticosteroids.
Idelalisib
Idelalisib is a selective inhibitor of adenosine-5’-triphosphate
in the phosphatidylinositol-3-kinase delta (PI3Kδ). It is
approved since 2014 in combination with rituximab for the
treatment of relapsed chronic lymphocytic leukemia (B-CLL)
and for first-line therapy of B-CLL with del17p or TP53
mutation and as a monotherapy for refractory follicular
lymphoma.
Phosphatidylinositol 3-kinase (PI3K) comprises a group
of related lipid enzymes regulating pleiotropic downstream
effector functions. Class I PI3Ks are heterodimers of reg-
ulatory and catalytic subunits with four different isoforms,
α, β, γ and δ, involved in cell proliferation, survival, and
motility [112, 113]. The α and β isoforms are widely
expressed in many tissues, whereas γ and δ isoforms are
restricted to hematopoietic cells. In B lymphocytes, the δ
isoform (PI3Kδ) plays a central role in normal B-cell
development and function, transducing signals from B-cell
receptor as well as from receptors for various cytokines,
chemokines and integrins [114, 115]. PI3Kδ signaling
pathways are frequently hyperactive in many B-cell
malignancies [116–118], so that the inhibition of δ
isoform-specific PI3K signaling is a promising approach for
the therapy of B-cell lymphoma. Idelalisib blocks PI3Kδ-
AKT (protein kinase B) signaling and promotes apoptosis
of B-lymphocytes.
Few reports describe a higher risk of opportunistic
infections in patients treated with idelalisib, particularly PcP
and CMV infections, even in the setting of normal neu-
trophil counts and absence of profound lymphocytopenia. It
was hypothesized that PI3K inhibitors cause an increased
susceptibility to infections through impairment of granulo-
cyte activation [119]. Four trials have been published on
monotherapy [120–123], three in combination with
anti CD20 [124–126] and four with other combinations
[127–130]; three of them were stopped early because of
excess adverse event rates (hepatotoxicity and pneumonitis)
[128–130].
Regarding bacterial infections, no increased risk was
found to be associated with idelalisib. For clinical practice,
no specific recommendations for antibacterial prophylaxis
can be given. Sehn et al. published a retrospective analysis
of 2198 patients receiving idelalisib alone or in combination
with co-therapy (anti-CD20 antibody or bendamustine+
rituximab) and patients receiving only co-therapy (anti-
CD20 ± bendamustine) [131]. The overall incidence of PcP
was 2.5% in patients on idelalisib ± co-therapy vs. 0.2% in
patients receiving anti-CD20 antibody alone or in combi-
nation with bendamustine (relative risk, 12.5). A correlation
between CD4 counts (e.g., <200 cells/µL) and an increased
risk of PcP was not observed. Only 1.2% of patients
receiving anti-Pneumocystis prophylaxis developed this
complication, as compared to 3.5% of those without pro-
phylaxis, and among the 20% of patients in whom
PcP prophylaxis was administered, no deaths occurred.
Thus, there is a small, but increased risk of PcP during
treatment with idelalisib. Prophylaxis with trimethoprim-
sulfamethoxazole is included in the label now, and the
European Society of Clinical Microbiology and Infectious
Diseases study group for infections in compromised hosts
(ESGICH) suggests PcP prophylaxis during idelalisib
therapy and for 2−6 months after its discontinuation [132].
From our perspective, PcP prophylaxis is recommended,
but based on weak evidence [133, 134].
Cytomegalovirus reactivations are notified in randomized
trials for 52 of 2204 patients (2.4%) treated with idelalisib
(https://www.ema.europa.eu/documents/variation-report/
zydelig-h-c-003843-a20-1439-0023-epar-assessment-
report-article-20_en.pdf) [123, 126, 127, 135]. The inci-
dence rate is higher when idelalisib is combined with
bendamustine (13/207 patients; 6.3%) (https://www.ema.
europa.eu/documents/variation-report/zydelig-h-c-003843-a
20-1439-0023-epar-assessment-report-article-20_en.pdf)
[127, 135]. CMV serostatus must be defined for all patients
before treatment initiation. For CMV-negative patients,
CMV-negative or filtered blood products are recommended
and CMV antigen or PCR should be checked at least every
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4 weeks. In case of positive PCR/antigen with increasing
viral load or symptoms consistent with CMV disease,
ganciclovir or valganciclovir treatment is recommended and
idelalisib should be discontinued [134].
Histone deacetylase (HDAC) inhibitors
(panobinostat, vorinostat, romidepsin)
HDAC inhibitors are used for epigenetic treatment affecting
the coiling and uncoiling of DNA around histones, invol-
ving histone acetyl transferases and histone deactetylases
[136]. For use in clinical hematology, panobinostat (in
combination with bortezomib and dexamethasone for
recurrent multiple myeloma), vorinostat (T-cell lymphoma
progressive, persistent or recurrent on or following two
systemic therapies) and romidepsin (treatment of relapsed
cutaneous T-cell lymphoma and peripheral T-cell lym-
phoma) are approved.
HDAC inhibitors exert a plethora of inhibitory
effects on innate immunity, in particular on toll-like
receptor-mediated dendritic cell (DC) and macrophage
function such as sensing, phagocytosis, cytokine pro-
duction or adhesion [137], resulting in increased micro-
bial susceptibility and reduced inflammatory response
[138]. However, in controlled clinical trials on HDAC
inhibitor use in patients with multiple myeloma, malig-
nant lymphoma (T cell, B cell or Hodgkin’s), acute
myeloid or lymphoblastic leukemia or myelodysplastic
syndrome, no significant increase in infection rates or
fever have been observed in comparison with control
groups [139–150]. A notable rate of asymptomatic inter-
stitial pneumonitis has been reported from a clinical trial
on panobinostat used for treatment of Waldenström’s
Macroglobulinemia [151]. From observations outside
clinical hematology, a potential use of HDAC inhibitors
for improved clearance of Human Immunodeficiency
Virus has been postulated [152–155].
For clinical practice, no clear evidence of HDAC
inhibitor-attributable increase in the risk of infection or
infection-related mortality has been reported. Hence, there
is no rationale for specific prophylaxis and for specific
diagnostic procedures in case of fever in hematologic
patients under treatment with HDAC inhibitors. Consider-
ing their negative impact on inflammatory response,
screening for HBV and consideration of prophylactic drug
treatment in case of reactivation risk may be recommended.
In patients with active infection, HDAC inhibitor treatment
should be withheld. In case of cough and/or dyspnea, drug-
related interstitial lung disease should be taken into con-
sideration. HDAC inhibitor use in HIV-positive patients
with hematologic malignancies does not seem to increase
the risk of HIV activation.
mTOR inhibitors (sirolimus, temsirolimus,
everolimus)
Inhibitors of the mammalian target of rapamycin (mTOR)
are approved for immunosuppression post solid organ
transplantation and the treatment of mantle cell lymphoma,
breast cancer, neuroendocrine tumors and renal cell cancer.
Sirolimus, temsirolimus and everolimus are available for
clinical application.
mTOR is acting as a serine/threonine protein kinase in
the PI3k/AKT signaling pathway of growth factor receptors
such as epidermal growth factor (including HER-2), vas-
cular endothelial growth factor and insulin-like growth
factor-1 receptor. Immunosuppression and impaired wound
healing may result from inhibition of T-cell proliferation,
antigen-presenting cells, B cells, neutrophil granulocytes,
mast cells and stromal cells [156, 157]. A meta-analysis of
published reports on 5436 patients treated with mTOR
inhibitors showed a nonsignificantly increased risk of all-
grade leukopenia and neutropenia [158], while another
meta-analysis of 3180 mTOR inhibitor-treated patients
[159] demonstrated a relative risk of all-grade and high-
grade infections of 2.00 (95% CI, 1.76−2.28, p < 0.001)
and 2.60 (95% CI, 1.54−4.41, p < 0.001), respectively, as
compared with patients in the control arms of the studies.
Infections mainly affect the respiratory tract (61.7%),
genitourinary tract (29.4%) and skin/soft tissue (4.2%).
A difference in incidences or risks between everolimus and
temsirolimus or between different tumor types (renal cell
carcinoma vs. others) was not observed. Among respiratory
tract infections, no increase in the risk of specific types of
pneumonia such as PcP, invasive mold or CMV infection
was found to be associated with mTOR inhibition [160].
Urinary tract infections caused by polyomavirus or
CMV were even less frequently observed in 4930 renal
transplant recipients receiving mTOR inhibitors as com-
pared with those treated with mycophenolate for preventing
graft rejection [161]. A meta-analysis of 14 clinical trials on
post-transplant mTOR inhibitor treatment confirmed a
lower rate of CMV reactivation among heart transplant
recipients [162].
Studies conducted in patients with metastatic cancers
(renal, breast or lung) reported mTOR inhibitor-related
pneumonitis with a large variation in incidence [163–165].
For clinical practice, no specific recommendations for
antimicrobial prophylaxis or for the diagnostic approach to
individual patients with fever emerging under treatment
with mTOR inhibitors can be given. In light of their overall
increased risk of infectious complications, a high level of
alertness is required. In patients who develop cough and/or
dyspnea, drug-related interstitial lung disease should be
taken into consideration.
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Ruxolitinib
Ruxolitinib is an inhibitor of Janus kinases (JAKs),
which are non-receptor tyrosine kinases mediating signal
transduction induced by cytokines. JAK2V617F mutation
results in constitutive activation of the JAK/STAT (signal
transducer and activator of transcription) signaling
pathway. Ruxolitinib alleviates constitutional symptoms
of myelofibrosis (MF) by downregulating interleukin
(IL)-1b, IL-6 and TNF-α. Ruxolitinib was approved for
treatment of advanced MF and Polycythaemia Vera (PV).
Until now, three possible mechanisms of ruxolitinib
immunomodulatory effects and immunosuppressive action
have been identified, mainly based on dendritic, T- and
natural killer (NK) cells. The first mechanism is the
ruxolitinib-induced effect on DCs differentiation and func-
tion in vitro and in vivo blocking DC development [166]. In
the presence of ruxolitinib, the cells morphologically and
phenotypically resemble monocytes rather than DCs, and IL
−12 cytokine production, which is critical for naive
CD8-positive T-cell activation to acquire cytotoxic activity
and to destroy infected or transformed cells, is markedly
reduced. Finally, proper DC migration to secondary lym-
phoid organs, in order to induce T-cell responses, is also
severely reduced [167].
The second mechanism involves T-cells. JAK/STAT-
signaling is involved in the regulation of CD4-positive
T cells, which mediate inflammatory responses and protect
against a wide range of pathogens by adopting a series of
distinct differentiated states, i.e., T helper cell type 1 (Th1),
Th2, Th17, regulatory T cells (Tregs), etc. Ruxolitinib
treatment significantly inhibits CD4+ T-cell activation and
differentiation [168, 169] reducing the number of proin-
flammatory Th1, Th17 and Tregs, that have also a protective
role against specific viral pathogens (e.g., HSV 2, lym-
phocytic choriomeningitis virus, West Nile virus), some
parasites (Plasmodium spp., Toxoplasma gondii) and fungal
pathogens (Candida albicans) [170].
The third immunosuppressive mechanism involves
NK cells probably because cytokine signals mediated
via the JAK/STAT pathway are determinant for NK
cell activation and maturation. In ruxolitinib-treated
patients, NK cell numbers are drastically reduced, in
part due to defective NK cell terminal maturation [171,
172], explaining the time-dependent decrease of NK cell
numbers during ruxolitinib intake. Ruxolitinib therapy is
associated with the reactivation of HSV and VZV infec-
tions, similar to patients with an inherited functional NK
cell deficiency [172].
Infections are among the main causes of morbidity and
mortality in MF, representing the cause of death in around
10% of the cases [173, 174], mainly in advanced stages of
disease.
The randomized COMFORT-I study [175] comprised
309 patients with splenomegaly and intermediate-2 or high-
risk IPSS who are probably more sensitive to infections
due to more advanced disease. Bacterial infections and in
particular urinary tract infections (9%) and VZV (1.9%)
were the main infections that occurred in patients receiving
ruxolitinib during randomized treatment. At 5-years follow-
up [176], the most severe infections were pneumonia and
sepsis at similar rates in patients treated with ruxolitinib or
placebo. Over time, VZV infections occurred at higher rate
in patients treated with ruxolitinib compared to placebo, but
the majority of cases were single episodes grade 1 or 2.
After 36 months, no other opportunistic infections occurred.
Similar results were obtained in the COMFORT-II trial
[177], in which ruxolitinib was compared with the best
available therapy in 219 patients. Pneumonia was the only
serious infectious adverse event reported (1% in the rux-
olitinib group vs. 5% in the “best available therapy” group).
The other infections were of grade 1−2. In the 5-year final
analysis [178], with a median duration of exposure to rux-
olitinib of 2.6 years, VZV infections (11.5%), pneumonia
(13%), sepsis (7.9%) and urinary tract infections (24.6%)
were found; however, grade 3 or 4 urinary tract infection
was reported only in 1.0% of patients, VZV in 4.3%, and no
trends towards an increase in the rate of sepsis were seen
over time. Two cases (1%) of tuberculosis (TB) were also
documented.
Other studies confirmed the predominance of bacterial
and viral infections besides sporadic opportunistic infec-
tions. The ROBUST trial [179], including 48 patients with
intermediate-1 and -2 and high risk, showed only bacterial
infections (urinary tract infections 16.7%, respiratory tract
infections 25%) or unexplained fever (12.5%), except one
case of PML. There were no reports of VZV, HBV or TB.
In the JUMP expanded-access trial [180], 1144 intermediate
and high-risk MF patients without access to ruxolitinib
outside of a clinical study were included. All-grade infec-
tions were mainly bacterial and viral and similar to those
present in the registry studies. TB was seen in three patients
(0.3%) and Legionella pneumonia in one patient (0.1%);
no HBV reactivation was reported. Among patients
with resistant PV and JAK2 mutation included in the
RESPONSE-1 trial [181], the rate of grade 3 or 4 infections
at week 32 was 3.6% and 2.7%, respectively, similar in both
ruxolitinib-treated patients and the control group treated
with the best available therapy; VZV infections, all of grade
1 or 2, occurred in seven patients in the ruxolitinib group
(6.4%) as compared with no patients receiving standard
therapy. Similar results were obtained from the randomized
study RESPONSE-2 [182] assessing 149 phlebotomy-
dependent patients resistant or intolerant to hydroxyurea,
74 in the ruxolitinib group versus 75 in the “best available
therapy” group. Among all patients, grade 3 infections were
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rare (two cases in the ruxolitinib group; influenza and
bronchitis) and one case (influenza) in the control group. No
pneumonia or TB reactivation was diagnosed in the rux-
olitinib group. Thus, ruxolitinib was not an independent risk
factor for infections in this study.
A recent retrospective analysis of 507 MF patients,
diagnosed between 1980 and 2014 in five Italian hematol-
ogy centers [183], described the epidemiology of infections
and the impact of ruxolitinib treatment in MF. One hundred
and twelve patients (22%) experienced 160 infectious
events (grade 3–4, 45%), more frequent in IPSS
intermediate-2 and high-risk patients and in those carrying
an unfavorable karyotype. The infections were mainly
bacterial (78%), viral (11%, more frequent in IPSS inter-
mediate-2/high-risk patients) and fungal (2%); also three
cases of TB infection (0.5%) were diagnosed. The fre-
quency of infections was significantly higher among the 128
patients treated with ruxolitinib (cumulative incidence rate
of 6.1% vs. 3.9 per patient-year). The type and site of
infections were similar to those observed in the general
population, but in ruxolitinib-treated patients, the rate of
infections (44% vs. 20%, p < 0.001) was higher compared
to ruxolitinib-untreated patients, probably also because
these patients were at IPSS intermediate-2/high-risk and
most (61.7%) carried a large splenomegaly, the two leading
risk factors identified for infections by multivariate analysis
in this study. Overall, infections were fatal in 9% of the
cases. Finally, in 70 patients with MF at lower risk (inter-
mediate-1) treated with ruxolitinib [184], after a median
time of 8 months from the start of ruxolitinib, infectious
complications >grade 2 were 15.9%, and were mainly
bacterial (with one bone TB infection) and viral infections.
Overall, these data confirm the predominance of bacterial
infections, in particular in the first months of treatment
(decreasing along treatment exposition) as well as in
patients who did not respond to ruxolitinib, while the VZV
infection rate increased over time up to 10−11%; infections
were mostly of grade 1−2. Some authors propose that
prophylaxis with antiviral drugs could be considered in case
of previous history of Herpes virus disease. Moreover, the
immunosuppressive effects of ruxolitinib may have played a
role in isolated cases of serious opportunistic infections
[185–196], such as PML [77], toxoplasmosis [186], CMV
[187], cryptococcosis [188–190], PcP and other fungal
infections [191–193], EBV [194, 195], VZV meningoen-
cephalitis [196] and, more frequently, reactivation of HBV
and TB.
The widespread use of molecularly targeted drugs with
immunosuppressive or immunomodulating action has
increased the risk of HBV reactivation, which may clini-
cally vary from an asymptomatic replication to severe
hepatitis and even fatal hepatic failure. The actual incidence
of HBV reactivation following ruxolitinib therapy is
unknown, because most clinical trials excluded the enroll-
ment of patients with active HBV. Until now, five case
reports are described in the literature [197–200], high-
lighting the importance of close monitoring of liver function
tests and plasma HBV-DNA level in HBV carriers receiving
ruxolitinib therapy. Recently published guidelines [201]
recommend HBV-screening for hematologic patients
scheduled for chemotherapy and/or immunotherapy for
both HBV reactivation and HBV risk factors as the first step
in preventing reactivation. Screening should include
HBsAg, anti-HBc and anti-HBs, and HBV-DNA if anti-
HBc is positive. HBV-seropositive individuals should be
started on antivirals in a timely manner. Recent guidelines
[36, 202, 203] recommend the use of antiviral drugs with a
higher barrier to resistance rather than lamivudine for first-
line treatment. Entecavir and tenofovir are now preferred
because of their lower viral resistance rates. The Centers for
Disease Control and Prevention (CDC) have recommended
routine postvaccination tests for anti-HBs and annual
booster doses for sustained immunity among high-risk
groups and immunocompromised individuals. Careful
assessment of HBV infection is required before starting
ruxolitinib, and monitoring of HBV markers and prophy-
laxis might be required for any patients that demonstrate an
HBV infection during the treatment course [204].
The notification of TB cases in registry data [177, 178]
and other studies [180, 183, 184] as well as case reports
[205–213] have suggested a causative role of ruxolitinib in
the emergence of tuberculosis. Before ruxolitinib treatment,
an accurate TB history should be always taken, and the
screening for latent TB must be considered if epidemiolo-
gical risk factors are significant (history, endemic areas,
trips in endemic areas) with Tuberculin Skin Test (TST)
or (preferably) IFN-γ Release Assay, IGRA (i.e. Quanti-
FERON test) [204, 208]. After commencing ruxolitinib,
regular follow-up of patients is advised, especially for the
first 6 months, to assess for the development of opportu-
nistic infections and TB reactivation. In the TB case reports,
anti-infectious treatment was effective in most patients and,
if clinically indicated, ruxolitinib was successfully resumed
[207, 208] after infection eradication, resulting in MF
improvement with no TB relapse.
In conclusion, ruxolitinib-treated patients should be
carefully evaluated for serious infections at the onset of
fever. Age and comorbidities, treatment modalities (such as
glucocorticosteroids), IPSS score [214] and environmental
exposure may further influence the risk of infections. Main
reported infections are bacterial, in particular urinary tract
infections, pneumonia, sepsis, and viral, in particular VZV
infection and influenza, but ruxolitinib was also associated
with a potentially increased risk of opportunistic infections.
As reported in a recent meta-analysis regarding ruxolitinib-
associated infections [215], severe infections may delay the
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eligibility of MF patients to allogeneic transplantation, so a
careful evaluation of the risk of infections is recommended
before ruxolitinib treatment.
HBV reactivation was occasionally seen in patients with
previous history of hepatitis and/or with occult infection.
Before ruxolitinib treatment, HBV screening in all patients
and prophylaxis preferably with entecavir in patients
HBsAg-positive and/or anti-HBc-positive is recommended.
Screening for latent TB should be considered if epidemio-
logical risk factors and medical history are significant.
In case of fever after ruxolitinib discontinuation, the
possibility of a rare “ruxolitinib withdrawal syndrome”, a
syndrome presenting respiratory distress, progression of
splenomegaly, fever or pruritus, mimicking an infection,
should be considered [216, 217].
Venetoclax
Venetoclax is a potent and specific inhibitor of the anti-
apoptotic BCL-2 protein. It has been approved for the
treatment of B-CLL (as third-line therapy or as second-line
therapy in case of 17p deletion or TP53 mutation), where it
has been shown to induce a rapid apoptosis of CLL cells,
known to be BCL-2 dependent [218].
The only immunosuppressive effect associated with
venetoclax is related to cytopenias. High-grade neutropenia
in particular has been shown to be a common adverse effect
in phase I and II studies in CLL [219, 220].
The relative role of venetoclax in this setting has been
questioned, as pretreatments and marrow infiltration by
CLL may have a substantial impact. Neutropenia occurs
mainly during the first 3 months of treatment, and an
inverse correlation has been shown between blood veneto-
clax concentration and risk of neutropenia and infection
[221]. Improvement may therefore be related to bone mar-
row clearance from B-CLL. However, the causal role of
venetoclax is highly probable. Venetoclax has been shown
to suppress granulopoiesis in vitro and in animal models
[222]. Moreover, comparative data from a phase 3 trial
comparing rituximab-venetoclax to rituximab-bendamustin
in relapsed or refractory CLL have shown a higher rate of
grade 3 or 4 neutropenia in the venetoclax group (57.7% vs.
38.8%) [223]. Interestingly, cyclic administration of vene-
toclax (1 week on therapy, 3 weeks off) was not associated
with neutropenia in a study on venetoclax use in systemic
lupus erythematosus [224].
The real risk of infections associated with venetoclax in
patients with B-CLL is unknown. In an aggregated safety
analysis including one phase 1 and two phase 2 studies of
venetoclax monotherapy in relapsed or refractory B-CLL,
the drug has shown a manageable safety profile. Grade 3 or
higher overall infection rate was 19% [225]. Reassuringly,
although neutropenia was more frequent, a lower rate of
grade 3 or 4 febrile neutropenia (3.6% vs. 9.6%) and grade
3 or 4 infections (17.5% vs. 21.8%) was reported with
rituximab−venetoclax in comparison to rituximab−bend-
amustin [223].
Neutropenia has usually been managed with dose
reduction or transient interruption, and G-CSF has been
used with good response [220, 226]. According to the
manufacturer, treatment should be withheld in case of
grade 4 hematologic toxicity or in case of grade 3 or 4
neutropenia with infection or fever [227]. Infection
without neutropenia has seldom led to venetoclax inter-
ruption or dose reduction [220].
Venetoclax is a substrate of CYP3A, raising concerns
about the impact of CYP3A inducers or inhibitors, such as
azole antifungal agents. The impact of posaconazole coad-
ministration has been well studied, and venetoclax dose
should be reduced by at least 75% [228].
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